StockData
Verastem, Inc. logo

Verastem, Inc. (VSTM) stock

VSTMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 3/30
$6.87−0.54 (-7.29%)

Close on Nov 18, 2026Market cap $622.17MP/E –Yield –

Verastem revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Verastem's revenue for the twelve months ending Jun 30, 2026 was $87.53M. For fiscal 2025 it was $30.91M, up 209.1% from the year before. The highest annual figure on record is $88.52M in fiscal 2020.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$30.91M+209.1%
FY2024Dec 31, 2024$10.00M+285.2%
FY2022Dec 31, 2022$2.60M+26.4%
FY2021Dec 31, 2021$2.05M-97.7%
FY2020Dec 31, 2020$88.52M+407.1%
FY2019Dec 31, 2019$17.46M-34.7%
FY2018Dec 31, 2018$26.72M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$40.08M+1775.4%
Q1 FY2026Mar 31, 2026$18.67M–
Q4 FY2025Dec 31, 2025$17.54M+75.4%
Q3 FY2025Sep 30, 2025$11.24M–
Q2 FY2025Jun 30, 2025$2.14M–
Q4 FY2024Dec 31, 2024$0–
Q1 FY2024Jun 30, 2024$10.00M+285.2%
Q4 FY2022Dec 31, 2022$0-100.0%
Q3 FY2022Sep 30, 2022$0-100.0%
Q2 FY2022Jun 30, 2022$0-100.0%
Q1 FY2022Mar 31, 2022$2.60M+158.1%
Q4 FY2021Dec 31, 2021$545.00K+7.7%
Q3 FY2021Sep 30, 2021$2.00K-100.0%
Q2 FY2021Jun 30, 2021$500.00K-88.4%
Q1 FY2021Mar 31, 2021$1.01M-80.1%
Q4 FY2020Dec 31, 2020$506.00K-86.0%
Q3 FY2020Sep 30, 2020$78.65M+770.8%
Q2 FY2020Jun 30, 2020$4.31M+37.3%
Q1 FY2020Mar 31, 2020$5.06M+202.6%
Q4 FY2019Dec 31, 2019$3.62M+198.9%
Q3 FY2019Sep 30, 2019$9.03M-41.8%
Q2 FY2019Jun 30, 2019$3.14M-68.6%
Q1 FY2019Mar 31, 2019$1.67M–
Q4 FY2018Dec 31, 2018$1.21M–
Q3 FY2018Sep 30, 2018$15.51M–
Q2 FY2018Jun 30, 2018$10.00M–

More Verastem figures

See a number that looks wrong?